Imatinib compared with second-generation tyrosine kinase-inhibitors in persons with chronic myeloid leukemia presenting in accelerated phase.
Yang S, Zhang X, Gale RP, Du X, Chen CY, Weng JY, Huang J, Li F, Zeng Y, Xiao Z, Hu JD, Yang LJ, Liu ZG, Li GH, Sun XL, Yang W, Feng R, Han YQ, Jing Y, Xu N, Liu XL, Liu ZF, Wang XD, Wu SX, Liang R, Zhang YL, Yang YF, Zhu HL, Pan L, Meng L, Zhao YH, Yi H, Liu YL, Zhang WH, Zheng YJ, Zhou ZP, Chen SN, Qiu HY, Li WM, Jia ZL, Bai YL, Lin LE, Liu BC, Liu CS, Luo JM, Meng JX, Sun ZQ, Zhang YQ, Huang XJ, Jiang Q.
Yang S, et al. Among authors: xu n.
Am J Hematol. 2023 Jul;98(7):E183-E186. doi: 10.1002/ajh.26943. Epub 2023 May 2.
Am J Hematol. 2023.
PMID: 37128776
Free article.
No abstract available.